Literature DB >> 31663152

A deadly trend in fentanyl fatalities (England, 1998-2017).

Hugh Claridge1, Bryn D Williams2, Caroline S Copeland1.   

Abstract

AIM: To identify trends in drug-related deaths associated with fentanyl and its derivatives, including novel variants, in England, 1998-2017.
METHODS: Case reports from the National Programme on Substance Abuse Deaths (NPSAD) where a pharmaceutical fentanyl or non-pharmaceutical fentanyl derivative (NPFD) was found at post-mortem and/or implicated in the death were extracted for analysis.
RESULTS: NPSAD has received case reports detailing 298 deaths in England from 1998-2017 where a fentanyl was found at post-mortem and/or implicated in the death. Hospital administered fentanyl is "very safe", whereas pharmaceutical fentanyls in the community, procured either legitimately via prescription or illegitimately, carry high risk of unintentional death. Deaths involving NPFDs, which possess extreme potencies in comparison to morphine, have drastically risen over the past three years, and correlate with an increasing number of available compounds. Males, and those with existing opioid abuse disorders, are particularly susceptible to death related to NPFD intake.
CONCLUSIONS: The increasing availability of both pharmaceutical fentanyls and NPFDs represents a serious risk to public health. Unintentional misuse of these compounds in England is contributing to the exponential increase in fentanyl-associated deaths that is being observed at the global scale.
© 2019 The British Pharmacological Society.

Entities:  

Keywords:  drug-related deaths; fentanyl; novel psychoactive substance; opioid overdose; synthetic opioid

Mesh:

Substances:

Year:  2020        PMID: 31663152      PMCID: PMC7080637          DOI: 10.1111/bcp.14135

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

Review 1.  Opioid receptors.

Authors:  Maria Waldhoer; Selena E Bartlett; Jennifer L Whistler
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

2.  A response to the opioid overdose epidemic: naloxone nasal spray.

Authors:  Daniel P Wermeling
Journal:  Drug Deliv Transl Res       Date:  2013-02-01       Impact factor: 4.617

3.  Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe.

Authors:  Jane Mounteney; Isabelle Giraudon; Gleb Denissov; Paul Griffiths
Journal:  Int J Drug Policy       Date:  2015-04-17

Review 4.  Fentanyl nasal spray for the treatment of cancer pain.

Authors:  Kyriaki Mystakidou; Irene Panagiotou; Athanasios Gouliamos
Journal:  Expert Opin Pharmacother       Date:  2011-05-24       Impact factor: 3.889

5.  Analytical evidence to show letters impregnated with novel psychoactive substances are a means of getting drugs to inmates within the UK prison service.

Authors:  Loretta T Ford; Jonathan D Berg
Journal:  Ann Clin Biochem       Date:  2018-03-30       Impact factor: 2.057

Review 6.  Analgesia in the surgical intensive care unit.

Authors:  Eric Ehieli; Suraj Yalamuri; Charles S Brudney; Srinivas Pyati
Journal:  Postgrad Med J       Date:  2016-10-24       Impact factor: 2.401

7.  Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic reservoir and Durogesic D-Trans matrix transdermal fentanyl patches.

Authors:  Nadine F J Van Nimmen; Hendrik A F Veulemans
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-10-09       Impact factor: 3.205

Review 8.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

9.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

10.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview.

Authors:  Stephen Ph Alexander; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; O Peter Buneman; John A Cidlowski; Arthur Christopoulos; Anthony P Davenport; Doriano Fabbro; Michael Spedding; Jörg Striessnig; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

View more
  5 in total

1.  Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis.

Authors:  Joseph Friedman; Fernando Montero; Phillippe Bourgois; Rafik Wahbi; Daniel Dye; David Goodman-Meza; Chelsea Shover
Journal:  Drug Alcohol Depend       Date:  2022-02-26       Impact factor: 4.852

Review 2.  Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.

Authors:  Amanda L A Mohr; Barry K Logan; Melissa F Fogarty; Alex J Krotulski; Donna M Papsun; Sherri L Kacinko; Marilyn A Huestis; Jeri D Ropero-Miller
Journal:  J Anal Toxicol       Date:  2022-07-14       Impact factor: 3.220

Review 3.  The fentanyl epidemic in Estonia: factors in its evolution and opportunities for a comprehensive public health response, a scoping review.

Authors:  Anneli Uusküla; Ave Talu; Sigrid Vorobjov; Maris Salekešin; Jürgen Rannap; Liis Lemsalu; Don Des Jarlais
Journal:  Int J Drug Policy       Date:  2020-05-13

4.  A deadly trend in fentanyl fatalities (England, 1998-2017).

Authors:  Hugh Claridge; Bryn D Williams; Caroline S Copeland
Journal:  Br J Clin Pharmacol       Date:  2020-01-23       Impact factor: 4.335

5.  Synthetic Cannabinoid-Related Deaths in England, 2012-2019.

Authors:  Pruntha Yoganathan; Hugh Claridge; Lucy Chester; Amir Englund; Nicola J Kalk; Caroline S Copeland
Journal:  Cannabis Cannabinoid Res       Date:  2021-02-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.